文献速递自身炎症与 IgG4 相关病

阿那白滞素治疗重症COVID-19的队列研究

Anakinra for severe forms of COVID-19: a cohort study.
PubMed 文献 · Lancet Rheumatol · 2020-05-29

该前瞻性队列联合历史对照研究评估了阿那白滞素治疗重症COVID-19的疗效。阿那白滞素组52例,历史对照组44例,主要终点为ICU有创机械通气或死亡复合终点。

要点

  • 阿那白滞素显著降低重症COVID-19患者ICU有创机械通气或死亡风险。
  • 转氨酶升高发生率两组相近(13% vs 9%),未报告严重不良反应。

核心结论

  • 阿那白滞素降低了重症COVID-19患者对ICU有创机械通气的需求及死亡率,且未出现严重副作用。

研究设计与样本

  • 前瞻性队列来自巴黎圣约瑟夫医院集团,历史对照组从该集团COVID队列中回顾性选取,该队列始于2020年3月18日。
  • 阿那白滞素组纳入2020年3月24日至4月6日连续52例成人重症COVID-19双侧肺炎患者,历史对照组44例,纳入标准相同。
  • 阿那白滞素组接受皮下注射阿那白滞素(100 mg每日两次共72小时,随后100 mg每日一次共7天)联合该机构当时的标准治疗;历史组接受标准治疗及支持治疗。
  • 主要分析基于意向性治疗原则,纳入阿那白滞素组至少接受一次注射的所有患者。

主要发现

  • 肝转氨酶升高在阿那白滞素组7例(13%),历史对照组4例(9%)。

关键数值与推荐

  • 纳入标准:年龄≥18岁,胸片或肺部CT显示重症COVID-19相关双侧肺炎,且实验室确诊SARS-CoV-2或肺部CT典型浸润影,并满足以下之一:氧流量≥6 L/min时血氧饱和度≤93%,或过去24小时内室内空气下血氧饱和度下降3%且氧流量3 L/min时饱和度≤93%。

临床怎么用

  • 对于重症COVID-19伴呼吸功能恶化且符合纳入标准的患者,可考虑超说明书使用阿那白滞素。
  • 使用阿那白滞素期间需监测肝转氨酶。
  • 疗效需通过对照试验进一步确认。

局限性

  • 历史对照设计可能存在混杂偏倚。
  • 样本量较小(阿那白滞素组52例,历史组44例)。
  • 作者指出需对照试验确认疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19. We aimed to assess the off-label use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of worsening respiratory function. METHODS: The Ana-COVID study included a prospective cohort from Groupe Hospitalier Paris Saint-Joseph (Paris, France) and a historical control cohort retrospectively selected from the Groupe Hospitalier Paris Saint-Joseph COVID cohort, which began on March 18, 2020. Patients were included in the prospective cohort if they were aged 18 years or older and admitted to Groupe Hospitalier Paris Saint-Joseph with severe COVID-19-related bilateral pneumonia on chest x-ray or lung CT scan. The other inclusion criteria were either laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and either an oxygen saturation of 93% or less under oxygen 6 L/min or more, or aggravation (saturation ≤93% under oxygen 3 L/min) with a loss of 3% of oxygen saturation in ambient air over the previous 24 h. The historical control group of patients had the same inclusion criteria. Patients in the anakinra group were treated with subcutaneous anakinra (100 mg twice a day for 72 h, then 100 mg daily for 7 days) as well as the standard treatments at the institution at the time. Patients in the historical group received standard treatments and supportive care. The main outcome was a composite of either admission to the intensive care unit (ICU) for invasive mechanical ventilation or death. The main analysis was done on an intention-to-treat basis (including all patients in the anakinra group who received at least one injection of anakinra). FINDINGS: From March 24 to April 6, 2020, 52 consecutive patients were included in the anakinra group and 44 historical patients were identified in the Groupe Hospitalier Paris Saint-Joseph COVID cohort study. Admission to the ICU for invasive mechanical ventilation or death occurred in 13 (25%) patients in the anakinra group and 32 (73%) patients in the historical group (hazard ratio [HR] 0·22 [95% CI 0·11-0·41; p<0·0001). The treatment effect of anakinra remained significant in the multivariate analysis (HR 0·22 [95% CI 0·10-0·49]; p=0·0002). An increase in liver aminotransferases occurred in seven (13%) patients in the anakinra group and four (9%) patients in the historical group. INTERPRETATION: Anakinra reduced both need for invasive mechanical ventilation in the ICU and mortality among patients with severe forms of COVID-19, without serious side-effects. Confirmation of efficacy will require controlled trials. FUNDING: Groupe Hospitalier Paris Saint-Joseph.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020. PMID: 32835245. doi:10.1016/S2665-9913(20)30164-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。